Moderna Raises 2026 Revenue Guidance and Reports 42% Melanoma Risk Reduction

What happened

Moderna raised its full-year 2026 revenue growth guidance to 15% to 25%, citing improved respiratory vaccine demand, and announced that intismeran reduced the risk of melanoma recurrence or death by 42% in the Phase 3 INTerpath-001 trial. The revenue outlook implies 2026 sales of roughly $2.2–$2.4B, up from $1.9B in 2025, but the company remains deeply unprofitable with a high fixed cost base. The 42% risk reduction provides a quantitative anchor to the positive melanoma data first reported in August and supports a near-term regulatory filing with Merck. These updates are positive but do not yet resolve the core concerns of manufacturing underabsorption, RSV uptake, or 2027 flu commercial execution. The next critical milestones remain formal melanoma submission, disclosed flu contracting, and cash burn trajectory into 2027.

Implication

Investors should hold rather than add. The raised revenue guidance validates that respiratory demand is converting better than the weak Q2 figures suggested, but the full-year outlook still implies a substantial operating loss and ongoing cash burn. The 42% melanoma risk reduction strengthens the probability of a successful filing, yet the value of a broad oncology franchise remains back-end loaded with NSCLC and other studies still enrolling. Entry remains more attractive on a pullback toward $115, while trimming makes sense if the stock exceeds $170 without operational evidence of 2027 flu contracting and cost absorption. The next 90 days should provide clarity on regulatory submission and early flu launch preparation, which are the real catalysts.

Thesis delta

The original WAIT thesis is unchanged. The melanoma data now includes a specific 42% risk reduction, increasing confidence in regulatory approval, and the revenue guidance raise shows respiratory execution is improving. However, neither event resolves the persistent financial losses, high fixed costs, or lack of visibility on 2027 flu and RSV conversion. Therefore, the attractive entry of $115 and trim above $170 remain appropriate.